Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
20.11.24
08:24 Uhr
0,075 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiKarolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics secures bridge financing2
MoKarolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents positive interim data from Phase 1b/2a clinical study1
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
FrKarolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines appoints Dr Gaston Picchio as acting CEO5
FrKarolinska Development AB (publ): Interim Report - January-September 202451STOCKHOLM - 15 November 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-September 2024. The full report is available on the Company's website....
► Artikel lesen
13.11.Karolinska Development AB (publ): Karolinska Development's Extraordinary General Meeting 20242
05.11.Karolinska Development AB (publ): Karolinska Development's portfolio company BOOST Pharma successfully completes pre-IND meeting with FDA and receives second tranche of investment82STOCKHOLM, SWEDEN, November 5 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has succesfully completed a pre-IND meeting with the...
► Artikel lesen
21.10.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines announces positive data from a phase 1 study of its universal Covid-19 vaccine48STOCKHOLM, SWEDEN, October 21, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines, has presented positive clinical safety and immunogenicity...
► Artikel lesen
15.10.Notice of Extraordinary General Meeting in Karolinska Development AB (publ)1
23.09.Karolinska Development AB (publ): Karolinska Development divests its holding in the Danish dermatology company Henlez1
17.09.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01107STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also completed...
► Artikel lesen
17.09.Karolinska Development AB (publ): Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease134STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical...
► Artikel lesen
30.08.Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG0052
30.08.Karolinska Development AB (publ): Interim Report - January-June 202497STOCKHOLM - 30 August 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-June 2024. The full report is available on the Company's website. "The successes...
► Artikel lesen
16.07.Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives EUR 17.5 million from the innovation program EIC Accelerator2
10.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition secures funding for continued clinical development of golexanolone1
12.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Biosergen gets final approval to test lead candidate BSG005 in patients with invasive fungal infection120STOCKHOLM, Sweden, June 12 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has received the final permission required to test its lead...
► Artikel lesen
28.05.Karolinska Development AB (publ): Karolinska Development invests in BOOST Pharma, expanding its portfolio1
26.04.Karolinska Development AB (publ): Interim Report - January-March 2024121STOCKHOLM - 26 April 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report - January-March 2024. The full report is available on the Company's website. "2024...
► Artikel lesen
14.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million264STOCKHOLM, SWEDEN, March 14, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company Aprea Therapeutics has received FDA approval of the company's IND application...
► Artikel lesen
16.02.Karolinska Development AB (publ): Year-end Report - January-December 2023230STOCKHOLM - 16 February 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report - January-December 2023. The full report is available on the Company's website....
► Artikel lesen
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1